Table. Minimum inhibitory concentrations of antimicrobials for the ceftriaxone-resistant, multidrug-resistant Neisseria gonorrhoeae isolate SE690, Sweden, September 2022.
| Antimicrobial | MIC (mg/L) | Interpretation (EUCAST v 13.0 [25]) |
|---|---|---|
| Ceftriaxone | 0.25 | Resistant |
| Cefixime | 1 | Resistant |
| Cefotaxime | 1 | Resistant |
| Ciprofloxacin | 8 | Resistant |
| Tetracycline | 32 | Resistant |
| Benzylpenicillin | > 32 | Resistant |
| Azithromycin | 0.5 | Susceptiblea |
| Spectinomycin | 16 | Susceptible |
| Gentamicin | 8 | NA (wild-type MIC) |
| Ertapenem | 0.016 | NA (wild-type MIC) |
| Zoliflodacinb | 0.064 | NA (wild-type MIC) |
| Lefamulinc | 0.125 | NA (wild-type MIC) |
MIC: minimum inhibitory concentration; EUCAST: European Committee on Antimicrobial Susceptibility Testing; NA: not applicable (due to lack of breakpoints for interpretation).
a Because clinical EUCAST breakpoints are lacking for azithromycin, EUCAST’s epidemiological cut-off (ECOFF) value of MIC > 1 mg/L for azithromycin was used to distinguish susceptibility from resistance [25].
b Pre-licensing international phase III randomised clinical trial [1,2] will finish in 2023.
c Novel antimicrobial with high in vitro activity against N. gonorrhoeae [3-5].